According to filings with the U.S. Securities and Exchange Commission, Leap Therapeutics is raising $77,219,193.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Douglas Onsi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Leap Therapeutics
Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. km Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. FL-301, is a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Leap also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15.

To learn more about Leap Therapeutics, visit http://www.leaptx.com/

Contact:
Douglas Onsi, President and Chief Executive Officer
617-252-4343

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.